Human T-cell leukemia virus type ? associated with an increased risk of primary malignant neoplasm

Main Article Content

Aya Nakaya
Shinya Fujita
Atsushi Satake
Takahisa Nakanishi
Yoshiko Azuma
Yukie Tsubokura
Akiko Konishi
Masaaki Hotta
Hideaki Yoshimura
Kazuyoshi Ishii
Tomoki Ito
Shosaku Nomura


human T-cell leukemia virus type І (HTLV-І), adult T-cell lymphoma (ATL), primary malignant neoplasm, regulatory T-cell(Treg)


The correlation between human T-cell leukemia virus type ? (HTLV-?) infection and malignant neoplasms other than adult T-cell lymphoma (ATL) remains unknown. We analyzed the frequency of primary malignant neoplasm in HTLV-?-seropositive patients. From January 2006 to December 2016, 203 patients were diagnosed as HTLV-?-seropositive at Kansai Medical University Hospital. Among them, 32 developed a primary malignant neoplasm. Their median age was 64 years old, 63% of them were male, and 69% of them were HTLV-I carriers. This group had the following distribution of ATL subtypes: 31% smoldering type, 0% chronic type, 3% acute type, and 3% lymphoma type. Among them, 53% was hematology malignancy, and solid tumor was 47%. The most frequent type of hematological malignancy was T-cell lymphoma (23%), followed B-cell lymphoma (16%), and myelodysplastic syndromes (6%). The most frequent primary solid tumor locations were the lung (15%), followed by the colon (9%), prostate (6%), kidney (6%), cervix (2%), breast (2%), liver (2%), pancreas (2%), and oral cavity (2%). Our results suggest that HTLV-?infection is often associated with the development of other malignant neoplasms. Therefore, HTLV-?-positive patients should be made aware of their increased risk for the onset of a malignant neoplasm and undergo increased surveillance.


Download data is not yet available.
Abstract 1779 | PDF Downloads 364 HTML Downloads 204


1) Asou N, Kumagai T, Uekihara S, Ishii M, Sato M, Sakai K, Nishimura H, Yamaguchi K, Takatsuki K. HTLV-I seroprevalence in patients with malignancy. Cancer. 1986; 58(4):903-907.
2) Imamura N, Inada T, Tagaya Y, Yodoi J, Kuramoto A. Socinski MA, Bondarenko I, Karaseva NA, et al. Association between ATL and non-hematopoietic neoplasms. Hematol Oncol. 1993 ;11(3):127-137.
3) Kozuru M, Uike N, Muta K, Goto T, Suehiro Y, Nagano M. High occurrence of primary malignant neoplasms in patients with adult T-cell leukemia/lymphoma, their siblings, and their mothers. Cancer. 1996 ;78(5):1119-1124.
4) Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991; 79(3):428-437.
5) Suefuji H, Ohshima K, Hayabuchi N, Nakamura K, Kikuchi M. HTLV-1 carriers with B-cell lymphoma of localized stage head and neck: prognosis, clinical and immunopathological features. Br J Haematol. 2003; 123(4):606-612.
6) Beltran BE, Quiñones P, Morales D, Revilla JC, Alva JC, Castillo JJ. Diffuse large B-cell lymphoma in human T-lymphotropic virus type 1 carriers. Leuk Res Treatment. 2012; 2012:262363.
7) [accessed Jan 24, 2018]
8) Kannagi M, Matsushita S, Shida H, Harada S. Cytotoxic T cell response and expression of the target antigen in HTLV-I infection. Leukemia. 1994; 8 Suppl 1:S54-59.
9) Ogura M, Ishida T, Tsukasaki K, Takahashi T, Utsunomiya A. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. Cancer Chemother Pharmacol. 2016; 78(1):199-207.
10) Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Kawano R, Suzumiya J, Utsunomiya A, Harada M, Kikuchi M. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol. 2004; 126(1):81-84.
11) Matsubara Y, Hori T, Morita R, Sakaguchi S, Uchiyama T. Phenotypic and functional relationship between adult T-cell leukemia cells and regulatory T cells. Leukemia. 2005; 19(3):482-483.